Abstract
High-grade gliomas are associated with a small risk of spontaneous intratumoral hemorrhage. A significant percentage of patients with high-grade glioma develop a deep venous thrombosis or pulmonary embolus, requiring anticoagulation. Because bevacizumab administration can be complicated by hemorrhage at the site of tumor or at other sites, a clinical concern for increasing the risk of intracranial hemorrhage arises when treating high-grade glioma patients who have a deep venous thrombosis or pulmonary embolus with therapeutic anticoagulation and concurrent bevacizumab. Evidence to date does not indicate that there is an increased risk of intracranial hemorrhage when bevacizumab is combined with anticoagulation in this setting.
Related Journals
Current Dentistry
Current Traditional Medicine
Adolescent Psychiatry
New Emirates Medical Journal
Current Radiopharmaceuticals
Recent Patents on Anti-Cancer Drug Discovery
Current Medicinal Chemistry - Anti-Cancer Agents
Current Cancer Therapy Reviews
Clinical Cancer Drugs
Anti-Cancer Agents in Medicinal Chemistry
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents